Výsledky vyhledávání - "Olwyn Deignan"

Akademický článek

Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study

Autor: Raymond S. McDermott, John Greene, John McCaffrey, Imelda Parker, Sylva Helanova, Anne-Marie Baird, Ausra Teiserskiene, Marvin Lim, Helen Matthews, Olwyn Deignan, John Feeney, Pierre G. Thirion, Stephen P. Finn, Paul J. Kelly

Publikováno v: Therapeutic Advances in Medical Oncology, Vol 13 (2021)

Background: Radium-223 and enzalutamide are approved agents for patients with metastatic castration-resistant prostate cancer (mCRPC). Combining radium-223 and enzalutamide to improve outcomes is of clinical interest due to their differing modes of a

Externí odkaz: https://doaj.org/article/9ecf3e519d8642928d0b391548f30aa3

Zobrazit plný text záznamu

Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study

Autor: Pierre Thirion, Paul J. Kelly, Helen Matthews, Anne-Marie Baird, Raymond S. McDermott, John Feeney, Olwyn Deignan, John Greene, Ausra Teiserskiene, John McCaffrey, Imelda Parker, Stephen P. Finn, Sylva Helanova, Marvin Lim

Publikováno v: Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 13 (2021)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41363785c4d79994afcc34a784ba8faf
http://europepmc.org/articles/PMC8427915

Zobrazit plný text záznamu

An updated analysis evaluating skeletal related events (SREs) in CTRIAL-IE 13-21: Phase II trial of radium-223 (R223) in combination with enzalutamide (ENZA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Autor: Anne-Marie Baird, Pierre Thirion, Stephen P. Finn, Ray McDermott, Paul J. Kelly, John Greene, Alison Bowes, John Feeney, Lisa Mary Prior, Imelda Parker, Marvin Chang Jui Lim, Ausra Teiserskiene, John McCaffrey, Olwyn Deignan

Publikováno v: Journal of Clinical Oncology. 37:215-215

215 Background: This phase II single arm study, previously reported on the safety and tolerability of the combination of R223 and ENZA in pts with mCRPC. R223 in combination with ENZA was well tolerated with acceptable safety and toxicity profiles. M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e7bb01a34e21e3cdc47e00f77d1f6663
https://doi.org/10.1200/jco.2019.37.7_suppl.215

Zobrazit plný text záznamu

Phase II safety and tolerability study of Radium-223 (R223) in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CTRIAL-IE (ICORG) 13-21

Autor: Raymond S. McDermott, Imelda Parker, Paul J. Kelly, Stephen P. Finn, John Greene, Olwyn Deignan, Pierre Thirion, Ausra Teiserskiene, John McCaffrey, Alison Bowes, John Feeney

Publikováno v: Journal of Clinical Oncology. 36:5050-5050

5050Background: R223 and ENZA are standard of care agents in the treatment of patients (pts) with mCRPC. The combination of R223 and ENZA is of interest due to differing modes of action and non-ove...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a27c0c1d39f61f518654d09b9a247137
https://doi.org/10.1200/jco.2018.36.15_suppl.5050

Zobrazit plný text záznamu

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303)

Autor: Martin R. Stockler, Scott Williams, Wendy Hague, Namrata Nayar, Xanthi Coskinas, Simon Hughes, Ray McDermott, Paul Kelly, Bertrand F. Tombal, Paul Nguyen, Nicola Jane Lawrence, Christopher Sweeney, Andrew J. Martin, Olwyn Deignan, Valerie Fonteyne, Ian D. Davis, Sonia Yip, Emily Tu

Publikováno v: Journal of Clinical Oncology. 36:TPS156-TPS156

TPS156 Background: Adjuvant ADT with an LHRH analog (LHRHA) given before, during and after radiotherapy (RT) is standard of care for high risk localised prostate cancer (PC). Enzalutamide improves overall survival (OS) in castration-resistant, metast

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d1d90c48daeb1b7d2b66f51bfb25cadc
https://doi.org/10.1200/jco.2018.36.6_suppl.tps156

Zobrazit plný text záznamu

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high-risk or node-positive prostate cancer: ENZARAD (ANZUP 1303)

Autor: Paul L. Nguyen, Simon Hughes, Andrew J. Martin, Vittorio Marchesin, Howard Chan, Martin R. Stockler, Scott Williams, Sonia Yip, Xanthi Coskinas, Nicola Jane Lawrence, Emily Tu, Wendy Hague, Olwyn Deignan, Christopher Sweeney, Ray McDermott, Ian D. Davis

Publikováno v: Journal of Clinical Oncology. 34:TPS5086-TPS5086

TPS5086Background: Adjuvant ADT with an LHRH analog (LHRHA) given before during and after radiotherapy (RT) is standard of care for high risk localised prostate cancer (PC). Enzalutamide is more ef...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c98d4ae497d26d3b0c4f14dd1e963c0e
https://doi.org/10.1200/jco.2016.34.15_suppl.tps5086

Zobrazit plný text záznamu

Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: The ANZUP ENZAMET Trial (ANZUP 1304)

Autor: Emily Tu, Scott A. North, Ray McDermott, Ian D. Davis, Simon Chowdhury, Andrew J. Martin, Alexander Montenegro, Wendy Hague, Francisco E. Vera-Badillo, Martin R. Stockler, Howard Chan, Olwyn Deignan, Vittorio Marchesin, Sonia Yip, Xanthi Coskinas, Nicola Jane Lawrence, Christopher Sweeney

Publikováno v: Journal of Clinical Oncology. 34:TPS5090-TPS5090

TPS5077 Background: Androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) or surgical castration, either alone or combined with conventional non-steroidal...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5beb983cc396cff4ae7ef861f1e02c67
https://doi.org/10.1200/jco.2016.34.15_suppl.tps5090

Zobrazit plný text záznamu

Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304)

Autor: Ian D. Davis, Martin R. Stockler, Andrew James Martin, Vittorio Marchesin, Olwyn Deignan, Ray McDermott, Wendy R. Parulekar, Scott A. North, Barbara Graham, Anne Poh Long, Felicia T Roncolato, Sonia Yip, Wendy Hague, Carlo Dazo, Xanthi Coskinas, Christopher Sweeney

Publikováno v: Journal of Clinical Oncology. 33:TPS5077-TPS5077

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::553ed860a41243ddc00d76b0dac00395
https://doi.org/10.1200/jco.2015.33.15_suppl.tps5077

Zobrazit plný text záznamu

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303)

Autor: Vittorio Marchesin, Sonia Yip, Felicia Roncolato, Anne Poh Long, Ian D. Davis, Xanthi Coskinas, Wendy Hague, Scott Williams, Emily Tu, Paul L. Nguyen, Christopher Sweeney, Ray McDermott, Martin R. Stockler, Olwyn Deignan, Andrew J. Martin

Publikováno v: Journal of Clinical Oncology. 33:TPS5078-TPS5078

TPS5078 Background: Adjuvant androgen deprivation therapy (ADT) including a luteinising hormone releasing hormone analogue (LHRHA) is standard of care given before, during, and after radiotherapy f...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::46668ed20d0ce81bd6a549e9a5db673b
https://doi.org/10.1200/jco.2015.33.15_suppl.tps5078

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání